|
시장보고서
상품코드
2016749
당뇨망막병증 시장 규모, 점유율, 동향 및 예측 : 유형별, 치료 유형별, 최종사용자별, 지역별(2026-2034년)Diabetic Retinopathy Market Size, Share, Trends and Forecast by Type, Treatment Type, End-User, and Region, 2026-2034 |
||||||
2025년의 세계 당뇨망막병증 시장 규모는 89억 달러로 평가되었습니다. 향후 IMARC Group은 2026년부터 2034년까지 CAGR 4.63%를 기록하며 2034년까지 시장 규모가 136억 달러에 달할 것으로 예측하고 있습니다. 북미는 현재 시장을 독점하고 있으며, 2025년에는 43.8% 이상의 큰 시장 점유율을 차지했습니다. 이는 높은 당뇨병 유병률, 높은 수준의 의료 인프라, 그리고 혁신적인 진단법 및 항VEGF 치료법의 조기 도입에 기인합니다. 지원적인 상환 정책과 강력한 R&D 투자로 인해 당뇨망막병증 시장에서 이 지역의 우위를 더욱 강화하고 있습니다.
당뇨망막병증(DR)은 빛을 감지하여 뇌에 신호를 보내는 눈의 부위인 망막에 영향을 미치는 당뇨병의 흔한 합병증입니다. 이는 고혈당으로 인해 망막의 미세혈관이 손상되어 혈관에서 삼출물이나 막힘이 발생하여 발생합니다. 치료를 소홀히 하면 시력저하와 실명으로 이어질 수 있습니다. 당뇨망막병증은 크게 비증식성 당뇨망막병증과 증식성 당뇨망막병증의 두 가지 유형이 있습니다. 진단을 위해 플루오레세인 형광안저조영술, 빛간섭단층촬영(OCT) 등의 검사를 포함한 종합적인 안과적 검사를 시행합니다. 이러한 검사는 DR의 유무와 중증도를 파악하는 데 도움이 되며, 조기 개입과 치료를 가능하게 합니다. 현재 DR에는 안구 내 스테로이드 주사, 레이저 치료, 유리체 절제술 등 여러 가지 치료법이 있습니다. 안구 내 스테로이드 주사는 안구 내 염증과 부종을 억제하는 데 도움이 되며, 레이저 치료는 누출된 혈관을 막아 망막의 추가 손상을 방지하는 데 사용됩니다. 더 심한 경우에는 안구 내 혈액과 흉터 조직을 제거하기 위해 유리체 절제술이 필요할 수 있습니다.
당뇨망막병증 시장 동향:
세계 당뇨망막병증 시장은 당뇨병 유병률의 증가와 고령 인구의 증가에 힘입어 괄목할 만한 성장세를 보이고 있습니다. 이에 따라 주요 기업들은 당뇨망막병증에 대한 새로운 치료법 개발에 적극 나서고 있으며, 이는 시장 성장을 견인하고 있습니다. 이 외에도 항VEGF제, 서방형 임플란트 등의 신약 및 신치료제 개발도 시장 성장에 크게 기여하고 있습니다. 또한, 당뇨망막병증 진단 및 치료에 있어 원격의료와 인공지능(AI)의 도입 확대도 시장 성장을 견인하고 있습니다. 당뇨망막병증과 그 잠재적 합병증에 대한 인식이 높아지면서 효과적인 치료법에 대한 수요가 증가하고 있는 것도 시장 성장을 촉진하는 요인으로 작용하고 있습니다. 또한, 당뇨망막병증의 조기 진단 및 치료에 대한 인식이 높아지고 안과 기술의 발전과 함께 시장 성장을 견인하고 있습니다. 이 외에도 의료비 증가, 안과 의료 서비스 향상을 위한 다양한 정부 정책 시행, 유리한 상환 정책 마련 등의 요인이 시장 성장을 견인하고 있습니다.
본 보고서에서 답변하는 주요 질문:
- 지금까지 세계 당뇨망막병증 시장은 어떤 추세를 보였으며, 향후 몇 년 동안 어떻게 변화할 것인가?
- 세계 당뇨망막병증 시장의 시장 촉진요인, 억제요인 및 기회는 무엇인가?
- 각 촉진요인, 제약요인 및 기회는 세계 당뇨망막병증 시장에 어떤 영향을 미치는가?
- 주요 지역 시장은 어디인가?
- 가장 매력적인 당뇨망막병증 시장을 가진 국가는 어디인가?
- 시장 유형별 시장 분석은 어떻게 되는가?
- 당뇨망막병증 시장에서 가장 매력적인 유형은 무엇인가?
- 치료 유형별 시장 현황은 어떻게 되는가?
- 당뇨망막병증 시장에서 가장 매력적인 치료법은 무엇인가?
- 최종사용자별 시장 분석은 어떻게 이루어지고 있는가?
- 당뇨망막병증 시장에서 가장 매력적인 최종사용자는 누구인가?
- 세계 당뇨망막병증 시장의 경쟁 구조는 어떤가?
- 세계 당뇨망막병증 시장의 주요 플레이어/기업은 어디인가?
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 당뇨망막병증 시장
제6장 시장 내역 : 유형별
제7장 시장 내역 : 치료 유형별
제8장 시장 내역 : 최종사용자별
제9장 시장 내역 : 지역별
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
제13장 경쟁 구도
KSM 26.05.06The global diabetic retinopathy market size was valued at USD 8.9 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 13.6 Billion by 2034, exhibiting a CAGR of 4.63% during 2026-2034. North America currently dominates the market, holding a significant market share of over 43.8% in 2025, owing to its high diabetes prevalence, advanced healthcare infrastructure, and early adoption of innovative diagnostics and anti-VEGF therapies. Supportive reimbursement policies and strong R&D investment further strengthen the region's dominance in the diabetic retinopathy market share.
Diabetic retinopathy (DR) is a common complication of diabetes that affects the retina, the part of the eye that senses light and sends signals to the brain. It occurs when high blood sugar levels damage the small blood vessels in the retina, causing them to leak or become blocked. This can lead to vision loss or blindness if left untreated. There are two main types of diabetic retinopathy, namely non-proliferative diabetic retinopathy and proliferative diabetic retinopathy. Its diagnosis involves a comprehensive eye exam, which may include tests such as fluorescein angiography and optical coherence tomography. These tests can help to identify the presence and severity of DR, allowing for early intervention and treatment. Currently, there are several treatment options available for DR, including the use of intraocular steroid injections, laser treatment, and vitrectomy. Intraocular steroid injections can help to reduce inflammation and swelling in the eye, while laser treatment can be used to seal leaking blood vessels and prevent further damage to the retina. In more severe cases, a vitrectomy may be necessary to remove blood or scar tissue from the eye.
Diabetic Retinopathy Market Trends:
The global diabetic retinopathy market is witnessing significant growth, primarily driven by the rising prevalence of diabetes and the increasing geriatric population. In line with this, key players are actively working to develop new therapeutic solutions for diabetic retinopathy, which is bolstering market growth. Apart from this, the development of new drugs and therapies, such as anti-VEGF agents and sustained-release implants, has also significantly contributed to market growth. Additionally, the escalating adoption of telemedicine and artificial intelligence (AI) in the diagnosis and treatment of diabetic retinopathy is driving the market growth. The rising demand for effective treatments due to the growing awareness of diabetic retinopathy and its potential consequences is acting as another growth-inducing factor. Furthermore, the surging awareness regarding early diagnosis and treatment of diabetic retinopathy, coupled with advancements in ophthalmic technology, are fueling the market growth. Other factors, such as increasing healthcare expenditure, the implementation of various government initiatives to improve eye care services, and the availability of favorable reimbursement policies, are propelling the market growth.
Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global diabetic retinopathy market report, along with forecasts at the global, regional and country level from 2026-2034. Our report has categorized the market based on type, treatment type and end-user.
Type Insights:
- Proliferative Diabetic Retinopathy
- Non-proliferative Retinopathy
Treatment Type Insights:
- Anti VEGF Drugs
- Steroid Implants
- Laser Surgeries
- Vitrectomy
End-User Insights:
- Hospitals and Pharmacies
- Eye Clinics
- Ambulatory Surgical Centres (ASCs)
- Others
Regional Insights:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. As per the report, North America dominates the market. Some of the factors accelerating the North America diabetic retinopathy market include the increasing prevalence of diabetes, growing awareness about diabetic retinopathy, and advancements in diagnostic and treatment technologies.
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global diabetic retinopathy market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Alimera Sciences, Allergan PLC, Ampio Pharmaceuticals, Bayer Healthcare, BCN Peptides, Genentech, Kowa Group, Novartis AG, Regeneron Pharmaceuticals Inc., Sirnaomics Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Questions Answered in This Report:
- How has the global diabetic retinopathy market performed so far, and how will it perform in the coming years ?
- What are the drivers, restraints, and opportunities in the global diabetic retinopathy market ?
- What is the impact of each driver, restraint, and opportunity on the global diabetic retinopathy market ?
- What are the key regional markets ?
- Which countries represent the most attractive diabetic retinopathy market ?
- What is the breakup of the market based on the type ?
- Which is the most attractive type in the diabetic retinopathy market ?
- What is the breakup of the market based on the treatment type ?
- Which is the most attractive treatment type in the diabetic retinopathy market ?
- What is the breakup of the market based on the end-user ?
- Which is the most attractive end-user in the diabetic retinopathy market ?
- What is the competitive structure of the global diabetic retinopathy market ?
- Who are the key players/companies in the global diabetic retinopathy market ?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Diabetic Retinopathy Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Type
- 6.1 Proliferative Diabetic Retinopathy
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Non-proliferative Retinopathy
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Treatment Type
- 7.1 Anti VEGF Drugs
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Steroid Implants
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Laser Surgeries
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Vitrectomy
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
8 Market Breakup by End-User
- 8.1 Hospitals and Pharmacies
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Eye Clinics
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Ambulatory Surgical Centres (ASCs)
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.1.1 United States
- 9.2 Asia Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.2.1 China
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.3.1 Germany
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.4.1 Brazil
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Competitive Landscape
- 13.1 Market Structure
- 13.2 Key Players
- 13.3 Profiles of Key Players
- 13.3.1 Alimera Sciences
- 13.3.1.1 Company Overview
- 13.3.1.2 Product Portfolio
- 13.3.1.3 Financials
- 13.3.2 Allergan Plc
- 13.3.2.1 Company Overview
- 13.3.2.2 Product Portfolio
- 13.3.2.3 Financials
- 13.3.2.4 SWOT Analysis
- 13.3.3 Ampio Pharmaceuticals
- 13.3.3.1 Company Overview
- 13.3.3.2 Product Portfolio
- 13.3.4 Bayer Healthcare
- 13.3.4.1 Company Overview
- 13.3.4.2 Product Portfolio
- 13.3.4.3 Financials
- 13.3.4.4 SWOT Analysis
- 13.3.5 BCN Peptides
- 13.3.5.1 Company Overview
- 13.3.5.2 Product Portfolio
- 13.3.5.3 Financials
- 13.3.6 Genentech
- 13.3.6.1 Company Overview
- 13.3.6.2 Product Portfolio
- 13.3.6.3 SWOT Analysis
- 13.3.7 Kowa Group
- 13.3.7.1 Company Overview
- 13.3.7.2 Product Portfolio
- 13.3.8 Novartis AG
- 13.3.8.1 Company Overview
- 13.3.8.2 Product Portfolio
- 13.3.9 Regeneron Pharmaceuticals Inc.
- 13.3.9.1 Company Overview
- 13.3.9.2 Product Portfolio
- 13.3.9.3 Financials
- 13.3.9.4 SWOT Analysis
- 13.3.10 Sirnaomics Inc.
- 13.3.10.1 Company Overview
- 13.3.10.2 Product Portfolio
- 13.3.1 Alimera Sciences
